Table 1.
Patient characteristics
| MSKCC (n=123) |
UCSF (n=45) | VICC (n=30) | Total (n=198) | |
|---|---|---|---|---|
| Age at diagnosis, median (range) | 63 (21-84) | 60 (36-91) | 59 (36-85) | 62 (21-91) |
| Male | 57 (46.3%) | 19 (42.2%) | 10 (33.3%) | 86 (43.4%) |
| Primary tumor location | ||||
| Extrahepatic bile duct | 14 (11.4%) | 7 (15.6%) | 7 (23.3%) | 28 (14.1%) |
| Gallbladder | 34 (27.6%) | 7 (15.6%) | 8 (26.7%) | 49 (24.8%) |
| Intrahepatic bile duct | 75 (61.0%) | 31 (68.8%) | 15 (50.0%) | 121 (61.1%) |
| Adenocarcinoma | ||||
| Yes | 113 (91.8%) | 43 (95.5%) | 29 (96.7%) | 185 (93.4%) |
| AJCC stage at diagnosis | ||||
| I/II | 17 (13.8%) | 8 (17.8%) | 10 (33.3%) | 35 (17.7%) |
| III/IV | 103 (83.7%) | 37 (82.2%) | 20 (55.7%) | 160 (80.8%) |
| Unknown | 3 (2.4%) | 0 | 0 | 3 (1.5%) |
| First line regimen | ||||
| GEMICS/GEMOX | 94 (76.4%) | 29 (60.4%) | 21 (70.0%) | 144 (72.7%) |
| Intrahepatic FUDR* | 6 (4.9%) | 0 | 0 | 6 (3.0%) |
| Adjuvant <6 mos. prior | 0 | 10 (22.2%) | 4 (13.3%) | 14 (7.1%) |
| Others | 23 (18.7%) | 6 (13.3%) | 5 (16.7%) | 34 (17.2%) |
Key: AJCC=American Joint Committee on Cancer; GEMCIS=combination of gemcitabine plus cisplatin; GEMOX=combination of gemcitabine plus oxaliplatin; FUDR=fluorodeoxyuridine
*
4 additional patients received FUDR plus systemic chemotherapy in first line and are included under first line regimens used